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Poster Session II S371associated with CMV serostatus in TOL patients. A multivariate
analysis including: acute GVHD, conditioning regimen, marrow
vs. PBSC; related vs. unrelated donor, matched vs. mismatched
donor, recipient age and time post-HCT was performed Table 1.
cGVHD patients had a profile consistent with T effector cell ac-
tivation that was not present in TOL.
The characteristic inflammatory environment, increased cytokine
production, immunosuppressive therapy and impaired T cell im-
mune reconstitution observed in cGVHD, may increase the risk of
CMV reactivation and subsequent upregulation of genes related to
T cell activation and effector functions. In contrast, tolerant patients
may have achieved greater immune reconstitution andmore effective
CMV surveillance and control.
T cell activation during cGVHD is a complex process that appears
to be influenced by latent CMV.
Table 1. Multivariate analysis
Active cGVHD TolerantCMV+ (n 5 17) vs
CMV-(n 5 21)CMV+ (n 5 11) vs
CMV-(n 5 19)ITK 0.023[
CD86 0.034[
PLCG1 0.033[
PIK3CB 0.005[
GZMB 0.024[
INFg 0.015[
IL4R 0.025YPTPN7 0.000[
PRF1 0.000[
GZMA 0.003[
PDCD1 0.008[
IL12RB1a 0.016[
IL12RB1b 0.000[Ydownregulated gene
[upregulated gene454
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Cyclosporine A (CsA) is a calcineurin inhibitor that is used to pre-
vent graft-versus-host disease (GVHD) following allogeneic hema-
topoietic stem cell (HSCT)/bone marrow transplantation (BMT).
While CsA is utilized for the prophylaxis of GVHD, many patients
develop GVHD while on, or after removal from therapy. A disorder
develops with clinical symptoms and pathology that is similar to al-
logeneicGVHDafter syngeneic BMTandCsA therapy and has been
termed, syngeneic GVHD (SGVHD). In mice, SGVHD is mediated
by CD4+ T cells and required an intact host microbiota for the dis-
ease to develop. Interestingly, it was recently shown that antibiotic-
responsive intestinal inflammation developed after cord blood stem
transplantation and treatment with calcineurin inhibitors as prophy-
laxis for the development of GVHD. Data will be presented that
demonstrates the induction of a GVHD-like disease following allo-
geneic BMT and CsA therapy in mice. We have termed this disease
CsA-induced pseudoGVHD (PGVHD). In this inducible disease,
pathology characteristic of GVHD occurs in the colon and liver.
Similar to the SGVHDmodel, increasedCD4+T cell responsiveness
against microbial antigens is associated with an increase in TH1/
TH17 immunity relative to control BMTanimals. Themechanism(s)
responsible for the induction of PGVHDare unknown.Whether the
development of this disorder is due to incomplete immunosuppres-
sion, altered immune regulation, generation of immunity against mi-
crobial antigens or a combination of these possibilities is currently
under investigation. The PGVHD model will shed light on thisquestion with an eye towards future development of novel therapies
to address this issue clinically.455
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Oral budenoside (BUD) is commonly used as a topical adjunct in
graft-versus-host-disease (GVHD) of the gastrointestinal tract.
BUD possesses a high ratio of topical-to-systemic activity that limits
steroid toxicity. It is, however, inactivated via cytochrome P450 iso-
enzymes so that concomitant administration of azoles which com-
pete for this enzyme increases its bioavailability. The clinical
significance of such increased bioavailability after hematopoietic
stem cell transplantation is unknown.
The development of iatrogenic Cushing’s syndrome in a patient
receiving allogeneic hemopoietic stem cell transplantation (al-
loHSCT) who was taking BUD as the sole source of steroids, led
us to explore the frequency of Cushing’s disease or other manifesta-
tions of significant systemic exposure to exogenous steroids in pa-
tients who had received alloHSCT and were receiving both BUD
and an azole drug.We reviewed the medical charts of the 60 patients
who received an alloHSCT between January 2008 and August 2011.
Five patients (Table-1) met the criteria of diagnosis of acute or
chronic GVHD; continuation of BUD for a further 21 days or
more after cessation of systemic steroids; and concomitant adminis-
tration of an azole drug. The charts were reviewed for evidence of
clinical development of iatrogenic Cushing’s syndrome and for evi-
dence of abnormalities in morning plasma cortisol levels and serum
glucose levels.
BUD was initiated at 9 mg per day and the dose was titrated ac-
cording to response. All these patients were receiving either flucona-
zole (n 5 3) or voriconazole (n 5 2) for fungal prophylaxis.All had
suppression of morning plasma cortisol consistent with systemic ab-
sorbtion and significant plasma levels of the topically applied drug.
The patients also had rapid (within 3 weeks) onset of iatrogenic
Cushing’s syndrome, with median weight gain of 5.7 kg (range 5
4-7.1 kg). All patients developed facial mooning, central obesity
and glucose intolerance. Plasma cortisol remained at 1 ug/dl even
when BUD was titrated to 3mg/day, at which time exacerbation of
GUT and/or skin GvHD was seen, necessitating dose escalation.
Absolute neutrophil and lymphocyte counts remained unchanged
with no increased infections.
Hence the effect of combining azole-drugs with BUD is to consis-
tently increase systemic levels of the steroid sufficiently to induce
Cushing’s syndrome, reducing the selective benefit of this ‘‘topical’’
agent for gut GvHD in patients receiving both agents.
Table 1. Patients characteristics on BUD alone
GVHD/ BUD alone Cushing’sPatient/transplant Treatment duration (days) manifestation52, M, AML,
MIUD in CR-2,
BU/CY/AL,
tacrolimus
Grade II aGvHD,
skin, gut, liver,
Limited cGvHD,
skin, gut,
Prednisone,
BUD571* Plasma
cortisol 5 1 ug/dl,
weight gain 5 5.7 kg,
facial mooning,
central obesity,
glucose intolerance51, M, AML,
MRD in active
disease, BU/CY,
MTX,
tacrolimus
Grade II aGvHD,
skin,gut,
prednisone,
BUD62 Plasma cortisol 5 1ug/dl,
weight gain 5 4 kg facial
mooning, central obesity,
glucose intolerance67, M, AML,
MUD in CR-2,
FL/MEL/AL,
tacrolimus
Grade II aGvHD,
skin, gut,
Limited cGvHD,
skin, gut,
prednisone,
BUD151* Plasma Cortisol 5 1ug/dl,
weight gain 5 4.7 kg,
facial mooning, glucose
intolerance(Continued )
